tirzepatide cvot trial 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What AHA 25: SURPASS-CVOT: Tirzepatide vs

That hormone, called GLP-1, sends a signal to your brain that you are full and slows how quickly food leaves your stomach, so you stay satisfied longer

[5] [6] The medication is a synthetic analog of human GLP-1, modified with an albumin side chain that extends its half-life to approximately one week, allowing for once-weekly subcutaneous administration or daily oral dosing

Lean mass preservation supports fat loss without excessive muscle degradation

Serious adverse events and severe hypoglycaemia Neither tirzepatide nor semaglutide were associated with an increased risk for serious adverse events when compared with placebo (ESM Fig

If you have a medical emergency, call 911

Specialty pharmacies that insurance companies designate for certain medications may offer different pricing, and some plans require you to use specific pharmacies to receive coverage